Влияние розувастатина на липидный обмен, микроциркуляцию и показатели центральной гемодинамики у больных с острым коронарным синдромом

1. Аронов Д.М. Лечение и практика атеросклероза. М.: Триада-Х, 2000.
2. Арутюнов Г.П. Статины и острые коронарные синдромы. Мы на пороге нового стандарта лечения. Клин. фармакол. и тер. 2001; 3 (10).
3. Горбачева Е.В., Задионченко В.С., Данилова Н.В., Шехян Г.Г. и др. Особенности периферической микрогемодинамики у больных нестабильной стенокардией и не-Q-инфарктом миокарда В кн.: Российский национальный конгресс кардиологов. М., 2000; с. 86.
4. Козлов В.И., Соколов В.Г. Исследование колебаний кровотока в системе микроциркуляции. Применение лазерной допплеровской флоуметрии в медицинской практике. Мат. II Всероссийского симпозиума. М.,1998; с. 8–14.
5. Саркисов К.Г, Дуфак Г.В. Лазерная допплеровская флоуметрия как метод оценки состояния кровотока в микрососудах. Методология флоуметрии. 1999: 9–14.
6. Селезнев С.А., Назаренко Г.И., Зайцев В.С. Клинические аспекты микроциркуляции. Л.: Медицина, 1995; с. 208.
7. Шевченко О.П., Шевченко А.О. Статины ингибиторы ГМГ-КоА-редуктазы. М.: Реафарм, 2003.
8. Blake GJ; Ridker PM. Inflammatory bio-markers and cardiovascular risk prediction. J Intern Med 2002; 252: 283–94.
9. Crouse JR. III. Thematic review series: patientoriented research; imaging atherosclerosis: state of the art. J Lipid Res 2006; 47: 1677–99.
10. Nissen SE, Nicholls SJ, Sipahi I et al. ASTEROID Investigators. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
11. Dupuis J. Mechanisms of acute coronary syndromes and the potential role of statins. Atheroscler 2001; 2 (Suppl.): 9–14.
12. Emerson M, Momi S, Paul W et al. Endogenous nitric oxide acts as a natural antithrombotic agent in vivo by inhibiting platelet aggregation in the pulmonary vasculature. Thromb Haemost 1999; 81: 961–6.
13. Jones PH, Davidson MH, Stein EA et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92: 152–60.
14. Jones PH, Hunninghake DB, Ferdinand KC et al. Statin Therapies for Elevated Lipid Levels Compared Across Doses to Rosuvastatin Study Group. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther 2004; 26: 1388–99.
15. Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail 2005: 1059–69.
16. Krum H, McMurray JJ. Statins and chronic heart failure: do we need a large-scale outcome trial? J Am Coll Cardiol 2002; 39: 156–73.
17. Laufs U, Fata VL, Liao JK. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxiamediated down-regulation of endothelial nitric oxide synthase. J Biol Chem 1997; 272: 31725–9.
18. Luo JD, Zhang WW, Zhang GP et al. Simvastatin inhibits cardiac hypertrophy and angiotensin-converting enzyme activity in rats with aortic stenosis. Clin Exp Pharmacol Physiol 1999; 26: 903–8.
19. Martin JH, Krum H. Statins and clinical outcomes in heart failure. Clin Sci (Lond) 2007; 113: 119–27.
20. Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295: 1556–65.
21. Pasternak RC, Smith SCJr, Bairey-Merz CN et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol 2002; 40: 567–72.
22. Ridker PM, Rifai N, Rose L et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New Eng J Med 2002; 347: 1557–65.
23. Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003; 108: 2292–7.
24. Schuster H, Barter PJ, Stender S et al. MERCURY I Study Group. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study. Am Heart J 2004; 147: 705–12.
25. Uretsky BF, Thygesen K, Armstrong PW et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation 2000; 102: 611–6.

В.С.Задионченко, Г.Г.Шехян, Н.Б.Шахрай, А.М.Щикота, А.А.Ялымов 

ГОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития РФ